Last updated 2026-07-27
- Went public on OTC Markets (IRME), Jan 2021
- Raised $5.5M Series A, Sep 2020
- Raised $500k grant led by Israel Innovation Authority, May 2025
Total raised
$10.7M
Last: Grant 2025-05
Stage
Public
Founded
2007
Headcount
3
HQ
Rosh Pinna, Israel
Sector
Health Tech & Life Sciences
About
IR-MED Inc. is an innovative medical technology company specializing in non-invasive, AI-driven diagnostic devices. The company develops a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. This technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue, which is then analyzed using the company's AI-based process to provide healthcare professionals with decision support in the assessment of various medical conditions. Their mission is to improve patient care through innovative, real-time biomarker analysis at the point of care, addressing critical markets such as pressure injury detection, diabetic foot ulcer assessment, drug level monitoring, and pediatric ear infection detection.
Funding history · 6 rounds · $10.7M total
2025-05
Grant
$500K
★ Israel Innovation Authority
2024-07
Grant
$500K
★ Israel Innovation Authority
2022-04
PIPE
$3.2M
2020-12
Follow-on PO
Undisclosed
2020-09
A Round
$5.5M
1969-12
Seed
$1.0M
Headcount over time
From 3 (2021-02) to 11 (2025-10) · +8 (+267%) · 19 points · source: Finder history + radar grounding
Q&A
- What is IR-MED's primary focus?
- IR-MED is a medical technology company that develops non-invasive, AI-driven diagnostic devices for real-time biomarker analysis of blood and tissue using infrared spectroscopy.
- When did IR-MED go public?
- IR-MED went public on the OTCQB in December 2020.
- What was the most recent grant received by IR-MED?
- In May 2025, IR-MED was awarded a $500,000 grant from the Israel Innovation Authority to advance its AI-Powered DiaSafe™ device for Diabetic Foot Ulcer Assessment.
- What is PressureSafe and its efficacy?
- PressureSafe is IR-MED's device for the early detection of pressure injuries. In February 2024, IR-MED reported 92% efficacy for PressureSafe™ in early, non-invasive, skin color agnostic detection of pressure injuries. A usability study with Clalit, Israel's largest HMO, showed PressureSafe™ reduced pressure injuries by 50%.
- Has IR-MED received FDA listing for PressureSafe?
- Yes, in April 2024, IR-MED’s PressureSafe™ received FDA Listing for the indication of a Decision Support Device for Pressure Injuries.
- What is the status of IR-MED's DiaSafe™ device?
- In November 2025, IR-MED Ltd. announced the launch of the first-in-human clinical trial of its DiaSafe™ device for Diabetic Foot Ulcer (DFU) Assessment.
- Who is the current CEO of IR-MED?
- In August 2024, IR-MED appointed Ran Ziskind as Chief Executive Officer.
- What recognition did IR-MED receive in August 2024?
- In August 2024, IR-MED won a Netty Award for Best Up-and-Coming Health Tech Company.
Team · 2
Yaniv Cohen
Founder · Co-Founder
Ronnie Klein
Founder · Co-Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Technologies
SensingOpticInfraredArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 Patents
Tags
non-invasivemedical-technologiespharma-companiespatent-pendingclinicshealthcare-providerspharmaceuticalsmedical-devicesearly-detectionmonitoringhospitalsinfraredsensorsartificial-intelligencedigital-healthcaremachine-learningchildrendiagnosticsopticsremote-monitoringulcers
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | ir-medical.com |
|---|---|
| linkedin.com/company/70900354 |
Identifiers & details
| Legal name | IR-Med Inc. |
|---|---|
| Founded | 2007-4 |
| Employees (exact) | 3 |
| Market cap | $2.9M |
| Status reason | Public on OTCQB on Dec, 2020; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2021-01-26 | OTC Markets | IRME |
Radar intelligence
Patents
| EPO | 416 |
|---|
Web history (Wayback)
| Domain | ir-medical.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514824952 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2012-09-27 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 3 — charge (3) |
| Registered address | יהלום .20 ראש פינה |
Recent registry events
| Date | Event |
|---|---|
| 2025-09-07 | סילוק שעבוד |
| 2025-09-04 | רישום שעבוד |
| 2025-09-04 | סילוק שעבוד |